COVID Pfizer vaccine induced adverse events for students in age bracket (12–17 years) is higher than any vaccine ever administered; Cases of myo/pericarditis (n = 253) included 129 after dose 1 and

124 after dose 2; 86.9% were hospitalized; 'in boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates’

Just so you know about this study too:

Via the Vaccine Adverse Event Reporting System (VAERS), researchers identified Pfizer-BioNTech myocarditis/pericarditis occurrence according to CDC criteria in 12-17 year olds.

Researchers reported: ‘risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity. In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates’

SOURCE:

https://onlinelibrary.wiley.com/doi/10.1111/eci.13759

‘Cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized. Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity. In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates.’